Skip to main content
. 2019 Jun 6;11(6):261. doi: 10.3390/pharmaceutics11060261

Figure 4.

Figure 4

Appearance of migrated ЕА.Hy926 cells (magnification ×100) after treatment with (a) L1/mock siRNA,(b) L1/anti-VEGFA siRNA, (c) L1/anti-VEGFR1 siRNA, (d) L1/anti-endoglin siRNA, (e) L1/anti-VEGFA siRNA + anti-VEGFR1 siRNA, (f) L1/anti-VEGFA siRNA+anti-endoglin siRNA complexes (200 nM siRNA), and (g) intact cells.